XSpray Pharma AB (ST:XSPRAY) — Market Cap & Net Worth
Market Cap & Net Worth: XSpray Pharma AB (XSPRAY)
XSpray Pharma AB (ST:XSPRAY) has a market capitalization of $119.72 Million (Skr1.11 Billion) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #18500 globally and #322 in its home market, demonstrating a -6.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XSpray Pharma AB's stock price Skr26.65 by its total outstanding shares 41742340 (41.74 Million). Analyse XSPRAY cash flow conversion to see how efficiently the company converts income to cash.
XSpray Pharma AB Market Cap History: 2017 to 2026
XSpray Pharma AB's market capitalization history from 2017 to 2026. Data shows change from $279.64 Million to $119.72 Million (-1.89% CAGR).
XSpray Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XSpray Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1141.69x
XSpray Pharma AB's market cap is 1141.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $279.64 Million | $331.55K | -$13.20 Million | 843.43x | N/A |
| 2018 | $316.25 Million | $277.00K | -$23.10 Million | 1141.69x | N/A |
Competitor Companies of XSPRAY by Market Capitalization
Companies near XSpray Pharma AB in the global market cap rankings as of May 4, 2026.
Key companies related to XSpray Pharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
XSpray Pharma AB Historical Marketcap From 2017 to 2026
Between 2017 and today, XSpray Pharma AB's market cap moved from $279.64 Million to $ 119.72 Million, with a yearly change of -1.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr119.72 Million | -15.26% |
| 2025 | Skr141.28 Million | -24.13% |
| 2024 | Skr186.20 Million | +3.62% |
| 2023 | Skr179.69 Million | -29.82% |
| 2022 | Skr256.05 Million | -11.08% |
| 2021 | Skr287.95 Million | -66.96% |
| 2020 | Skr871.48 Million | +133.17% |
| 2019 | Skr373.75 Million | +18.18% |
| 2018 | Skr316.25 Million | +13.09% |
| 2017 | Skr279.64 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of XSpray Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $119.72 Million USD |
| MoneyControl | $119.72 Million USD |
| MarketWatch | $119.72 Million USD |
| marketcap.company | $119.72 Million USD |
| Reuters | $119.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more